Pathophysiology And Classification

  • Definition: A life-threatening hyperinflammatory syndrome caused by severe, uncontrolled activation of cytotoxic T-lymphocytes (CD8+ CTLs), natural killer (NK) cells, and histiocytes/macrophages, resulting in massive cytokine storm, hemophagocytosis, and progressive multiorgan failure.
  • Classification:
flowchart TD
    A["Hemophagocytic Lymphohistiocytosis (HLH)"] --> B["<b>Primary (Familial) HLH</b><br>• Autosomal recessive genetic mutations<br>• Presents in neonates and infants < 1 year<br>• Invariable recurrence; 100% fatal without HSCT"]
    A --> C["<b>Secondary (Acquired) HLH</b><br>• Precipitated by infectious, autoimmune, or malignant triggers<br>• Can occur at any age<br>• May resolve with trigger control + immunomodulation"]
    
    B --> D["<b>FHL Subtypes:</b><br>• FHL-2: <i>PRF1</i> (Perforin defect, ~30%)<br>• FHL-3: <i>UNC13D</i> (Munc13-4 vesicle priming)<br>• FHL-4: <i>STX11</i> (Syntaxin-11 fusion)<br>• FHL-5: <i>STXBP2</i> (Munc18-2 vesicle docking)<br>• Pigmentary Syndromes: Griscelli-2, Chediak-Higashi, Hermansky-Pudlak-2<br>• XLP-1 (<i>SH2D1A</i>) and XLP-2 (<i>XIAP</i>)"]
    
    C --> E["<b>Triggers:</b><br>• Infections: EBV (most common), CMV, HSV, Leishmania (Kala-Azar)<br>• Autoimmune: Systemic JIA (Macrophage Activation Syndrome / MAS)<br>• Malignancy: T-cell and B-cell lymphomas, leukemias"]

Diagnostic Criteria (HLH-2004 Guidelines)

The diagnosis of HLH is established if EITHER Criterion 1 or Criterion 2 is fulfilled:

Criterion 1: Molecular Genetic Confirmation

A molecular diagnosis consistent with HLH (pathogenic mutation identified in PRF1, UNC13D, STX11, STXBP2, RAB27A, LYST, SH2D1A, etc.).

Criterion 2: Clinical & Laboratory Criteria (At Least 5 of 8 Met)

  1. Fever: Persistent high spiking fever $\ge 38.5^\circ\text{C}$ for $>7\text{ days}$.
  2. Splenomegaly: Palpable spleen $\ge 3\text{ cm}$ below left costal margin.
  3. Cytopenias Affecting $\ge 2$ Lineages in Peripheral Blood:
    • Hemoglobin $<9.0\text{ g/dL}$ (in infants $<4$ weeks: $<10.0\text{ g/dL}$).
    • Platelets $<100,000/\mu\text{L}$.
    • Absolute Neutrophil Count (ANC) $<1,000/\mu\text{L}$.
  4. Hypertriglyceridemia and/or Hypofibrinogenemia:
    • Fasting serum triglycerides $\ge 265\text{ mg/dL}$ ($\ge 3.0\text{ mmol/L}$).
    • Serum fibrinogen $\le 150\text{ mg/dL}$ ($\le 1.5\text{ g/L}$).
  5. Hemophagocytosis: Demonstrated in bone marrow, spleen, lymph nodes, or liver, with absence of malignant cell infiltration. (Absence of hemophagocytosis on initial marrow does NOT rule out HLH; serial bone marrow aspirates are often required).
  6. Low or Absent NK-Cell Cytotoxic Activity: Measured by flow-based chromium-51 release or CD107a degranulation assay.
  7. Hyperferritinemia: Serum ferritin $\ge 500\ \mu\text{g/L}$. (In clinical practice, ferritin $>2,000–3,000\ \mu\text{g/L}$ carries $>90\%$ sensitivity, and ferritin $>10,000\ \mu\text{g/L}$ is $>95\%$ specific for HLH in pediatric intensive care).
  8. Elevated Soluble CD25 (sIL-2 Receptor): $\ge 2,400\text{ U/mL}$ (or age-adjusted laboratory reference limits; reflects profound in vivo T-cell activation).

High-Yield Comparison: HLH vs. Sepsis vs. MAS

ParameterSeptic Shock with MOFHemophagocytic Lymphohistiocytosis (HLH)Macrophage Activation Syndrome (MAS in sJIA)
Primary DriverBacterial / fungal infectionUnregulated cytotoxic T-cell & macrophage activationComplication of active rheumatological disease (sJIA, SLE)
Serum FerritinMildly elevated ($500–1,000\ \mu\text{g/L}$)Markedly elevated ($>3,000\text{ to }>10,000\ \mu\text{g/L}$)Extremely elevated (frequently $>10,000–50,000\ \mu\text{g/L}$)
Fibrinogen & ESRNormal or elevated (acute phase reactant)Low fibrinogen, low or paradoxically falling ESRParadoxically low/falling ESR despite worsening inflammation (due to fibrinogen consumption)
Platelets & LiverDisseminated intravascular coagulation (DIC)Severe thrombocytopenia + transaminitisSevere thrombocytopenia + elevated liver enzymes
Diagnostic MarkerPositive blood culture, elevated procalcitoninElevated soluble CD25 (sIL-2R), low CD107a2016 EULAR/ACR MAS criteria (Ferritin $>684$ + any 2 of platelet, AST, triglyceride, fibrinogen)

Stepwise Management Protocols

flowchart TD
    A["Suspected HLH (Diagnostic Criteria Met / Deteriorating Patient)"] --> B["<b>Immediate Supportive Stabilization & Workup:</b><br>• Blood cultures, EBV/CMV viral load, Leishmania testing<br>• CSF examination (pleocytosis, protein, hemophagocytosis)<br>• Broad-spectrum antimicrobials + IVIG (1 g/kg) while evaluating"]
    
    B --> C{"Identify Underlying Trigger & Subtype"}
    
    C -->|"EBV-Driven HLH / Severe Secondary HLH"| D["<b>HLH-94 Induction Protocol (8 Weeks):</b><br>• <b>Etoposide (VP-16):</b> 150 mg/m² IV twice weekly for weeks 1–2, then weekly<br>• <b>Dexamethasone:</b> 10 mg/m²/day tapering over 8 weeks<br>• Add <b>Cyclosporine A</b> from week 9 (trough 200–300 mcg/L)"]
    
    C -->|"Macrophage Activation Syndrome (MAS / sJIA)"| E["<b>Anti-IL-1 / Steroid First-Line:</b><br>• Pulse IV Methylprednisolone (30 mg/kg/day x 3 days)<br>• <b>Anakinra (IL-1 blocker):</b> 5–10 mg/kg/day SC/IV<br>• Cyclosporine A"]
    
    C -->|"Refractory Primary / EBV HLH"| F["<b>Targeted Second-Line Immunotherapy:</b><br>• <b>Emapalumab</b> (Anti-IFN-γ antibody)<br>• <b>Ruxolitinib</b> (JAK1/2 inhibitor) OR Alemtuzumab (anti-CD52)"]
    
    D --> G{"Primary / Familial HLH or Unresolved EBV?"}
    G -->|"Yes"| H["<b>Allogeneic Hematopoietic Stem Cell Transplant (HSCT)</b><br>The ONLY definitive curative therapy for primary HLH"]
    G -->|"No (Resolved Secondary HLH)"| I["Discontinue therapy after 8 weeks; monitor for recurrence"]

1. The HLH-94 Induction Regimen

  • Etoposide (VP-16): $150\text{ mg/m}^2$ IV (in infants $<10\text{ kg}$: $5\text{ mg/kg}$); administered twice weekly during weeks 1–2, then once weekly during weeks 3–8. Etoposide specifically eliminates hyperactive, cytokine-producing CD8+ T-lymphocytes and suppresses topoisomerase II.
  • Dexamethasone: Initial dose $10\text{ mg/m}^2/\text{day}$ orally or IV, tapered sequentially over 8 weeks ($10\text{ mg/m}^2$ for 2 weeks, $5\text{ mg/m}^2$ for 2 weeks, $2.5\text{ mg/m}^2$ for 2 weeks, $1.25\text{ mg/m}^2$ for 1 week, and 1 week of taper to off). Dexamethasone crosses the blood-brain barrier effectively.
  • Intrathecal Chemotherapy: Indicated if abnormal CSF (pleocytosis $>5\text{ cells}/\mu\text{L}$ or elevated protein) or progressive neurological symptoms persist after 2 weeks of systemic therapy: Intrathecal Methotrexate (dose by age: $<1\text{y}: 6\text{ mg}$; $1–2\text{y}: 8\text{ mg}$; $2–3\text{y}: 10\text{ mg}$; $>3\text{y}: 12\text{ mg}$) $\pm$ hydrocortisone.

2. Targeted Biologics & Modern Advances

  • Emapalumab (Gamifant):
    • First FDA-approved drug specifically for primary HLH with refractory, recurrent, or progressive disease.
    • Fully human IgG1 monoclonal antibody that binds and neutralizes Interferon-gamma (IFN-$\gamma$), the master inflammatory driver of hemophagocytic cascades.
    • Starting dose: $1\text{ mg/kg}$ IV twice weekly, escalating up to $10\text{ mg/kg}$ based on clinical response and serum CXCL9 levels.
  • Anakinra (Recombinant IL-1 Receptor Antagonist): First-line therapy for MAS complicating systemic JIA ($2–10\text{ mg/kg/day}$ divided q6–12h SC or IV); rapidly halts hyperferritinemic inflammation with low myelosuppressive toxicity.
  • Ruxolitinib (JAK1/2 Inhibitor): Oral inhibitor blocking downstream signaling of IFN-$\gamma$, IL-2, and IL-6; demonstrated high salvage rates in refractory pediatric secondary and EBV-associated HLH.

3. Definitive Cure: Allogeneic Stem Cell Transplantation (HSCT)

  • Mandatory for all confirmed cases of primary / familial HLH, persistent secondary HLH with genetic variants, and recurrent EBV-HLH.
  • Reduced-Intensity Conditioning (RIC) using Fludarabine + Melphalan + Alemtuzumab/Treosulfan yields superior survival ($>75–85\%$) compared to legacy myeloablative busulfan regimens by significantly reducing transplant-related mortality.